PT2854849T - Formulações estabilizadas contendo anti-anticorpos anti-dll4 - Google Patents

Formulações estabilizadas contendo anti-anticorpos anti-dll4

Info

Publication number
PT2854849T
PT2854849T PT137307021T PT13730702T PT2854849T PT 2854849 T PT2854849 T PT 2854849T PT 137307021 T PT137307021 T PT 137307021T PT 13730702 T PT13730702 T PT 13730702T PT 2854849 T PT2854849 T PT 2854849T
Authority
PT
Portugal
Prior art keywords
formulations containing
containing anti
dll4 antibodies
stabilized formulations
stabilized
Prior art date
Application number
PT137307021T
Other languages
English (en)
Inventor
Dix Daniel
Walsh Scott
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2854849(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PT2854849T publication Critical patent/PT2854849T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
PT137307021T 2012-05-31 2013-05-31 Formulações estabilizadas contendo anti-anticorpos anti-dll4 PT2854849T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261653478P 2012-05-31 2012-05-31

Publications (1)

Publication Number Publication Date
PT2854849T true PT2854849T (pt) 2018-05-09

Family

ID=48670784

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137307021T PT2854849T (pt) 2012-05-31 2013-05-31 Formulações estabilizadas contendo anti-anticorpos anti-dll4

Country Status (29)

Country Link
US (1) US9675692B2 (pt)
EP (1) EP2854849B1 (pt)
JP (1) JP6144758B2 (pt)
KR (1) KR20150033615A (pt)
CN (1) CN104349791A (pt)
AR (1) AR092325A1 (pt)
AU (1) AU2013267301B2 (pt)
BR (1) BR112014028997A2 (pt)
CA (1) CA2872275C (pt)
CL (1) CL2014003237A1 (pt)
CO (1) CO7151478A2 (pt)
DK (1) DK2854849T3 (pt)
EA (1) EA029779B1 (pt)
ES (1) ES2668900T3 (pt)
HK (1) HK1207305A1 (pt)
IL (1) IL235468A0 (pt)
LT (1) LT2854849T (pt)
MA (1) MA37645B1 (pt)
MX (1) MX357146B (pt)
NO (1) NO2887943T3 (pt)
NZ (1) NZ702288A (pt)
PH (1) PH12014502429A1 (pt)
PL (1) PL2854849T3 (pt)
PT (1) PT2854849T (pt)
SG (1) SG11201407171XA (pt)
SI (1) SI2854849T1 (pt)
TW (1) TWI609696B (pt)
UY (1) UY34842A (pt)
WO (1) WO2013181486A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
KR102091293B1 (ko) 2011-09-23 2020-03-20 온코메드 파마슈티칼스, 인크. Vegf/dll4 결합제 및 그의 용도
EP3212233B1 (en) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
JP6781508B2 (ja) * 2014-11-18 2020-11-04 塩野義製薬株式会社 安定化されたペプチド組成物
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
CN113474360A (zh) 2019-02-18 2021-10-01 伊莱利利公司 治疗性抗体制剂
US20220031843A1 (en) * 2020-07-08 2022-02-03 Regeneron Pharmaceuticals, Inc. Stabilized Formulations Containing Anti-CTLA-4 Antibodies

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
ES2190087T3 (es) 1997-06-13 2003-07-16 Genentech Inc Formulacion estabilizada de un anticuerpo.
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
EP1314437B1 (en) 2000-08-11 2014-06-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
SI1475101T1 (sl) 2002-02-14 2011-03-31 Chugai Pharmaceutical Co Ltd Farmacevtski proizvodi iz raztopine, ki vsebuje protitelo
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PT2586459T (pt) 2005-03-25 2017-07-25 Regeneron Pharma Formulações antagonistas de fcev
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
EP3753548A1 (en) 2006-06-16 2020-12-23 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
EP2081960B1 (en) 2006-10-27 2018-06-27 Ablynx N.V. Intranasal delivery of polypeptides and proteins
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
BRPI1006519A2 (pt) 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
ES2700450T3 (es) * 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
KR101333276B1 (ko) 2009-11-20 2013-11-27 센트로 데 인무노로지아 몰레큘라 항체의 제제
JP5964249B2 (ja) * 2010-03-02 2016-08-03 アッヴィ・インコーポレイテッド 治療用dll4結合タンパク質
SG189220A1 (en) * 2010-10-06 2013-05-31 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies

Also Published As

Publication number Publication date
KR20150033615A (ko) 2015-04-01
NZ702288A (en) 2016-12-23
CA2872275C (en) 2021-05-18
TWI609696B (zh) 2018-01-01
MX2014014363A (es) 2015-02-05
BR112014028997A2 (pt) 2017-07-25
CA2872275A1 (en) 2013-12-05
TW201400130A (zh) 2014-01-01
AR092325A1 (es) 2015-04-15
JP2015520173A (ja) 2015-07-16
DK2854849T3 (en) 2018-04-30
LT2854849T (lt) 2018-05-10
AU2013267301B2 (en) 2018-02-08
MA37645B1 (fr) 2018-10-31
US9675692B2 (en) 2017-06-13
ES2668900T3 (es) 2018-05-23
MA37645A3 (fr) 2017-07-31
CN104349791A (zh) 2015-02-11
EP2854849B1 (en) 2018-02-28
US20130323260A1 (en) 2013-12-05
MX357146B (es) 2018-06-28
AU2013267301A1 (en) 2014-12-18
CL2014003237A1 (es) 2015-07-10
EA029779B1 (ru) 2018-05-31
WO2013181486A1 (en) 2013-12-05
NO2887943T3 (pt) 2018-05-05
CO7151478A2 (es) 2014-12-29
EA201492186A1 (ru) 2015-08-31
UY34842A (es) 2013-12-31
PH12014502429B1 (en) 2015-01-12
IL235468A0 (en) 2014-12-31
EP2854849A1 (en) 2015-04-08
PH12014502429A1 (en) 2015-01-12
PL2854849T3 (pl) 2018-07-31
JP6144758B2 (ja) 2017-06-07
HK1207305A1 (en) 2016-01-29
MA37645A2 (fr) 2016-08-31
SG11201407171XA (en) 2014-11-27
SI2854849T1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
IL276234B (en) Antibody compositions
HK1204631A1 (en) Stabilized formulations containing anti-ang2 antibodies ang-2
HK1203146A1 (en) Antibody formulation
SI3117837T1 (sl) Formulacije protiteles
IL235807A0 (en) Immunoprecipitates containing anti–cd79b antibodies
RS60794B1 (sr) Stabilne formulacije koje sadrže anti-pcsk9 antitela
IL235989A0 (en) Immunoprecipitates containing anti–cd79b antibodies
IL230282B (en) Stable formulations containing anti-9pcsk antibody field
IL235468A0 (en) Stabilized formulations containing anti-dll4 antibodies
HK1204948A1 (en) Radiation-sterilization-resistant protein composition
ZA201404909B (en) Stabilized formulations containing anti-ang2 antibodies